Page 243 - Genentech News Today

New York, NY (PRWEB) November 02, 2022 -- The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of San Francisco

CHICAGO (PRWEB) November 02, 2022 -- To provide comprehensive information and a user-friendly experience to the millions of low vision patients, their

Although serum glial fibrillary acid protein (GFAP) could be a useful complement to the multiple sclerosis biomarker neurofilament light chain (NfL), it is not ready for the clinic, experts say.

Biocon Ltd, an innovation-led global biopharmaceuticals company, announced today it has been named among the Top 10 employers in the global biotech, pharma and biopharma sector by the prestigious U.S.- based Science magazine.

/PRNewswire/ -- LUNGevity Foundation, the nations leading lung cancer-focused nonprofit organization, today celebrates the second year of its...

Investegate announcements from ,

Stereotactic body radiotherapy plus sorafenib led to a strong survival benefit vs sorafenib alone in advanced hepatocellular carcinoma.

The first randomized trial of a disease-modifying therapy in radiological isolated syndrome, the earliest pre-clinical phase of MS, suggests dimethyl fumarate reduced the risk of a first clinical event by 80%.

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2022 Earnings Conference Call October 31, 2022 8:30 AM ET Company Participants Markus Georgi – Senior Vice President-Investor Relations Michael...

How Genentech is reaching out to people with MS differently. From PR Week